TY - JOUR T1 - Omicron and vaccines: An analysis on the decline in COVID-19 mortality JF - medRxiv DO - 10.1101/2022.05.20.22275396 SP - 2022.05.20.22275396 AU - Blas J. Larrauri AU - Alejandro Malbrán AU - José A. Larrauri Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/05/23/2022.05.20.22275396.abstract N2 - The SARS-CoV-2 virus emerged in December 2019 infecting more than 430 million people worldwide and causing almost 6 million deaths until February 2022. Rapid vaccination efforts during this period coincided with a reduction in the mortality rate of the virus. A new genetic COVID-19 variant named Omicron appeared and widely spread by the end of 2021, after which the COVID-19 mortality rate showed a marked, albeit temporary, decline. The potential relationship between vaccines and omicron infection on the mortality rate of COVID-19 is analyzed in this article using online data from public sources from countries with relatively high incidence of infection. Mortality and incidence rates were compared before and after Omicron became the prevalent source of COVID-19 cases, as well as the effect of vaccination during these periods. Infection rates were higher during Omicron than in the pre-Omicron period (4.16% vs. 2%, respectively), whereas mortality rates showed the opposite trend both in deaths over population (0.021% vs. 0.171%) and deaths over positive cases (0.27% vs. 1.07%, respectively). The results suggest that vaccines, while significantly reducing mortality, did not prevent Omicron infection; and that during the Omicron period mortality decreased by a low aggressiveness of this variant.Key Messages* Vaccines do not appear to have prevented Omicron infection.* Infection rates were higher during the Omicron period than before it.* Mortality rates were lower during the Omicron period than before it.* Vaccines reduced mortality rates during both pre- and Omicron periods.* The sharp decrease in mortality rates during the Omicron period seems to be due to the low virulence of Omicron strains rather than vaccine efficacy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data was obtained from the website Our World in Data, and all the data is still available on the web https://ourworldindata.org/ ER -